Skip to content

Considerations and Methods for Placebo Controls in Surgical Trials (ASPIRE Guidelines)

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)828-838
Number of pages11
JournalThe Lancet
Issue number10226
DateAccepted/In press - 20 Nov 2019
DatePublished (current) - 7 Mar 2020


Placebo comparisons are increasingly being considered for randomised trials
assessing the efficacy of surgical interventions. The aim of this paper is to provide a summary of current knowledge on placebo controls in surgical trials.
A placebo control is a complex type of comparison group and, although powerful, presents many challenges in a surgical setting. This review outlines what a placebo surgical control entails and our understanding of the placebo phenomenon in the context of surgery. It considers when placebo-surgical controls are acceptable (and when they are desirable) in terms of ethical arguments and regulatory requirements, how a placebo-surgical control should be designed, how to identify and mitigate risk for participants in placebo surgical trials, how such trials should be conducted and interpreted. Use of placebo control is justified in randomised controlled trials of surgical interventions provided there is a strong scientific and ethical rationale. Surgical placebos may be most appropriate where there is poor evidence on the efficacy of the procedure and a justified concern that results of a trial would be associated with high risk of bias, particularly due to the placebo effect. Feasibility work is recommended to optimise RCT design and conduct. This review forms an outline for best practice and provides guidance, in the form of the ASPIRE (Applying Surgical Placebo in Randomised Evaluations) checklist, for those considering the use of a placebo-control in a surgical randomised controlled trial.



  • Full-text PDF (accepted author manuscript)

    Rights statement: This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at . Please refer to any applicable terms of use of the publisher.

    Accepted author manuscript, 2.91 MB, PDF document

    Embargo ends: 7/09/20

    Request copy

    Licence: CC BY-NC-ND


View research connections

Related faculties, schools or groups